# US 2023/0407403 A1 · Method for assisting determination on suitability of esophageal cancer for endoscopic therapy, method for determining suitability of esophageal cancer for endoscopic therapy, method for collecting data for use in determination on suitability of esophageal cancer for endoscopic therapy, method for diagnosing suitability of esophageal cancer for endoscopic therapy, in vitro method for assisting determination on suitability of esophageal cancer for endoscopic therapy, ... > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2023/0407403 A1 - Document ID: US20230407403A1 - Status: Published application - Kind: A1 - Application number: 18/036,733 - Filed: 2021-11-08 - Published: 2023-12-21 - Earliest claimed: 2020-11-17 - Assignees: Public University Corporation Nagoya City University - Applicants: Public University Corporation Nagoya City University - Inventors: Takaya Shimura; Yusuke Okuda; Hiromi Kataoka - Web page: https://patentgrep.com/patent/US20230407403A1 ## CPC - C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575) - G01N 33/5753: of the stomach or small intestine - C12Q 2600/112: Disease subtyping, staging or classification - C12Q 2600/158: Expression markers - G01N 2333/515: Angiogenesic factors; Angiogenin - G01N 2333/522: Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4 or KC - G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis - C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES - G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q) ## Abstract The present invention provides a versatile method which has a high diagnostic accuracy rate on the suitability of esophageal cancer for endoscopic therapy and enables the simple and objective determination of the suitability or unsuitability for endoscopic therapy. In the method according to one aspect of the present invention, an expression level of at least one or more selected from the group consisting of CXCL2 and VEGFA in a sample collected from a subject is measured, and the expression level is compared with a reference value; the diagnostic kit according to one aspect of the present invention comprises a reagent for measuring at least one or more selected from the group consisting of the expression level of CXCL2 in the sample and the expression level of VEGFA in the sample; in the method for treating esophageal cancer according to one aspect of the present invention, the degree of vertical invasion of esophageal cancer in a subject is determined by employing a method in which an expression level of at least one or more selected from the group consisting of CXCL2 and VEGFA in a sample collected from a subject is measured and the expression level is compared with a reference value. ## Claims ### Claim 1 A method for assisting determination on suitability of esophageal cancer for endoscopic therapy, the method comprising: measuring an expression level of at least one or more selected from the group consisting of CXCL2 and VEGFA in a sample collected from a subject, and comparing the expression level with a reference value. ### Claim 2 A method for determining suitability of esophageal cancer for endoscopic therapy, the method comprising: measuring an expression level of at least one or more selected from the group consisting of CXCL2 and VEGFA in a sample collected from a subject, and comparing the expression level with a reference value. ### Claim 3 A method for collecting data for use in determination on suitability of esophageal cancer for endoscopic therapy, the method comprising: measuring an expression level of at least one or more selected from the group consisting of CXCL2 and VEGFA in a sample collected from a subject, and comparing the expression level with a reference value. ### Claim 4 A method for diagnosing suitability of esophageal cancer for endoscopic therapy, the method comprising: measuring an expression level of at least one or more selected from the group consisting of CXCL2 and VEGFA in a sample collected from a subject, and comparing the expression level with a reference value. ### Claim 5 A method for testing on suitability of esophageal cancer for endoscopic therapy, the method comprising: measuring an expression level of at least one or more selected from the group consisting of CXCL2 and VEGFA in a sample collected from a subject, and comparing the expression level with a reference value. ### Claim 6 An in vitro method for assisting determination on suitability of esophageal cancer for endoscopic therapy, the method comprising: measuring an expression level of at least one or more selected from the group consisting of CXCL2 and VEGFA in a sample collected from a subject, and comparing the expression level with a reference value. ### Claim 7 A method for diagnosing suitability of esophageal cancer for endoscopic therapy, the method comprising: measuring an expression level of at least one or more selected from the group consisting of CXCL2 and VEGFA in a sample collected from a subject, and comparing the expression level with a reference value. ### Claim 8 (depends on 7) The method according to claim 7, wherein expression levels of both CXCL2 and VEGFA in the sample are measured. ### Claim 9 (depends on 7) The method according to claim 7, wherein the sample is at least one or more selected from the group consisting of serum, a serum exosome, and tumor tissue. ### Claim 10 (depends on 7) The method according to claim 7, wherein the method assists determining whether or not esophageal cancer has invaded an esophageal vessel or a submucosa. ### Claim 11 A diagnostic kit that is used to determine suitability of esophageal cancer for endoscopic therapy, the diagnostic kit comprising: a reagent kit that is used for measuring at least one or more selected from the group consisting of an expression level of CXCL2 in a sample and an expression level of VEGFA in a sample. ### Claim 12 (depends on 7) A method for treating esophageal cancer, wherein a degree of vertical invasion of esophageal cancer in a subject is determined using the method according to claim 7, and endoscopic therapy is selected in a case where esophageal cancer is predicted not to have invaded an esophageal vessel. ### Claim 13 (depends on 7) A method for treating esophageal cancer, wherein a degree of vertical invasion of esophageal cancer in a subject is determined using the method according to claim 7, and endoscopic therapy is selected in a case where esophageal cancer is predicted not to have invaded a submucosa. ### Claim 14 (depends on 7) A method for treating esophageal cancer, wherein a degree of vertical invasion of esophageal cancer in a subject is determined using the method according to claim 7, and surgical therapy is selected in a case where esophageal cancer is predicted to have invaded an esophageal vessel or esophageal cancer is predicted to have invaded a submucosa.